Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02892318 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

A Phase 1 study of Acute Myeloid Leukemia, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
8
Study locations

NCT02892318 is a Phase 1 study of Acute Myeloid Leukemia that has completed, run by Hoffmann-La Roche. The registered enrollment target is 40 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (66% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02892318, a Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
8
Study locations

Study Summary

This is a non-randomized, open-label, Phase Ib study of atezolizumab in combination with immunomodulatory agents for the treatment of participants with AML (relapsed/refractory and treatment-naive, elderly participants unfit for induction chemotherapy). The study has been designed with the intent, over time, to study multiple combinations of atezolizumab with different immunomodulatory agents in participants with AML. The study will begin with the evaluation of the combination of atezolizumab and guadecitabine (Arm A). In the future, additional arms may be added.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Atezolizumab
  • DRUG Guadecitabine

Study Locations (8)

New York

  • The NewYork-Presbyterian Hospital Columbia University Medical Center - New York
  • Memorial Sloan Kettering Cancer Center - New York

California

  • City of Hope - Duarte

Connecticut

  • Yale University - New Haven

North Carolina

  • Levine Cancer Institute - Charlotte

Pennsylvania

  • Temple University Hospital - Philadelphia

Utah

  • Huntsman Cancer Institute - Salt Lake City

Wisconsin

  • The University of Wisconsin School of Medicine and Public Health - Madison

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2016-10-31
Est. Completion 2019-12-12
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02892318

The ClinicalTrials.gov registry entry for NCT02892318 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (66% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT02892318 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02892318 about?

NCT02892318 is a clinical study titled "A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)". This is a non-randomized, open-label, Phase Ib study of atezolizumab in combination with immunomodulatory agents for the treatment of participants with AML (relapsed/refractory and treatment-naive, elderly participants unfit for induction chemotherapy). The study has been designed with the intent, o...

What is the current status of trial NCT02892318?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-10-31. Estimated completion is 2019-12-12.

What conditions does trial NCT02892318 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT02892318?

The interventions under investigation include: Atezolizumab (DRUG), Guadecitabine (DRUG).

Who is sponsoring clinical trial NCT02892318?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02892318 being conducted?

This trial has 8 study locations across California, Connecticut, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.